CL2014000489A1 - Forma de cristal anhidra de rilapladib, forma 3; composicion farmaceutica que lo comprende; combinacion farmaceutica; su uso en el tratamiento de la enfermedad de alzheimer. - Google Patents
Forma de cristal anhidra de rilapladib, forma 3; composicion farmaceutica que lo comprende; combinacion farmaceutica; su uso en el tratamiento de la enfermedad de alzheimer.Info
- Publication number
- CL2014000489A1 CL2014000489A1 CL2014000489A CL2014000489A CL2014000489A1 CL 2014000489 A1 CL2014000489 A1 CL 2014000489A1 CL 2014000489 A CL2014000489 A CL 2014000489A CL 2014000489 A CL2014000489 A CL 2014000489A CL 2014000489 A1 CL2014000489 A1 CL 2014000489A1
- Authority
- CL
- Chile
- Prior art keywords
- rilapladib
- alzheimer
- disease
- treatment
- pharmaceutical composition
- Prior art date
Links
- NNBGCSGCRSCFEA-UHFFFAOYSA-N 2-[2-[(2,3-difluorophenyl)methylsulfanyl]-4-oxoquinolin-1-yl]-n-[1-(2-methoxyethyl)piperidin-4-yl]-n-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]acetamide Chemical compound C1CN(CCOC)CCC1N(C(=O)CN1C2=CC=CC=C2C(=O)C=C1SCC=1C(=C(F)C=CC=1)F)CC1=CC=C(C=2C=CC(=CC=2)C(F)(F)F)C=C1 NNBGCSGCRSCFEA-UHFFFAOYSA-N 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229950004360 rilapladib Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Glass Compositions (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530104P | 2011-09-01 | 2011-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014000489A1 true CL2014000489A1 (es) | 2014-08-01 |
Family
ID=46829730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014000489A CL2014000489A1 (es) | 2011-09-01 | 2014-02-27 | Forma de cristal anhidra de rilapladib, forma 3; composicion farmaceutica que lo comprende; combinacion farmaceutica; su uso en el tratamiento de la enfermedad de alzheimer. |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US9227953B2 (https=) |
| EP (1) | EP2751094B1 (https=) |
| JP (1) | JP6199291B2 (https=) |
| KR (2) | KR20190075172A (https=) |
| CN (1) | CN103906744A (https=) |
| AU (2) | AU2012300841C1 (https=) |
| BR (1) | BR112014004251A2 (https=) |
| CA (1) | CA2847066C (https=) |
| CL (1) | CL2014000489A1 (https=) |
| CO (1) | CO6890102A2 (https=) |
| CR (1) | CR20140098A (https=) |
| CY (1) | CY1120784T1 (https=) |
| DK (1) | DK2751094T3 (https=) |
| DO (1) | DOP2014000042A (https=) |
| EA (1) | EA027972B1 (https=) |
| ES (1) | ES2686563T3 (https=) |
| HR (1) | HRP20181375T1 (https=) |
| HU (1) | HUE041578T2 (https=) |
| IL (1) | IL230977A (https=) |
| LT (1) | LT2751094T (https=) |
| MA (1) | MA35362B1 (https=) |
| MX (1) | MX349243B (https=) |
| MY (1) | MY172885A (https=) |
| PE (1) | PE20141411A1 (https=) |
| PH (1) | PH12014500382A1 (https=) |
| PL (1) | PL2751094T3 (https=) |
| PT (1) | PT2751094T (https=) |
| RS (1) | RS57644B1 (https=) |
| SG (1) | SG2014011886A (https=) |
| SI (1) | SI2751094T1 (https=) |
| SM (1) | SMT201800455T1 (https=) |
| UA (1) | UA114607C2 (https=) |
| WO (1) | WO2013030374A1 (https=) |
| ZA (1) | ZA201401176B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103906744A (zh) | 2011-09-01 | 2014-07-02 | 葛兰素集团有限公司 | 新晶型 |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| TW202144329A (zh) * | 2020-03-30 | 2021-12-01 | 大陸商江蘇亞虹醫藥科技股份有限公司 | 硝羥喹啉前藥的晶型、含其的醫藥組成物及其製備方法和應用 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| FR2634376B1 (fr) | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
| IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| WO1993025190A1 (en) | 1992-06-10 | 1993-12-23 | Eastman Kodak Company | Surface modified nsaid nanoparticles |
| NZ248813A (en) | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
| US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5340564A (en) | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
| US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| US5560931A (en) | 1995-02-14 | 1996-10-01 | Nawosystems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5571536A (en) | 1995-02-06 | 1996-11-05 | Nano Systems L.L.C. | Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids |
| US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
| US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
| US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| US5718919A (en) | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| US5747001A (en) | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
| US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
| CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
| GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
| WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| GB0024808D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| EP1735457A4 (en) | 2004-04-16 | 2007-08-29 | Glaxo Group Ltd | METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY |
| AU2008251467B2 (en) | 2007-05-11 | 2014-07-31 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
| WO2008140450A1 (en) * | 2007-05-11 | 2008-11-20 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| CN101986785A (zh) * | 2007-05-11 | 2011-03-16 | 托马斯杰弗逊大学 | 治疗和预防神经退行性疾病和紊乱的方法 |
| US20080279846A1 (en) | 2007-05-11 | 2008-11-13 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| US8871928B2 (en) | 2010-09-20 | 2014-10-28 | Glaxo Group Limited | Tricyclic compounds, preparation methods, and their uses |
| JP2013544854A (ja) | 2010-12-06 | 2013-12-19 | グラクソ グループ リミテッド | 化合物 |
| PE20140421A1 (es) | 2010-12-06 | 2014-04-26 | Glaxo Group Ltd | COMPUESTOS DERIVADOS DE PIRIMIDINONA COMO INHIBIDORES DE Lp-PLA2 |
| EP2651403B1 (en) | 2010-12-17 | 2020-12-02 | Glaxo Group Limited | Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases |
| CN103906744A (zh) * | 2011-09-01 | 2014-07-02 | 葛兰素集团有限公司 | 新晶型 |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
-
2012
- 2012-08-31 CN CN201280051671.XA patent/CN103906744A/zh active Pending
- 2012-08-31 JP JP2014527685A patent/JP6199291B2/ja not_active Expired - Fee Related
- 2012-08-31 MY MYPI2014700470A patent/MY172885A/en unknown
- 2012-08-31 PT PT12756693T patent/PT2751094T/pt unknown
- 2012-08-31 PE PE2014000274A patent/PE20141411A1/es not_active Application Discontinuation
- 2012-08-31 EA EA201490536A patent/EA027972B1/ru not_active IP Right Cessation
- 2012-08-31 ES ES12756693.3T patent/ES2686563T3/es active Active
- 2012-08-31 WO PCT/EP2012/067027 patent/WO2013030374A1/en not_active Ceased
- 2012-08-31 UA UAA201403151A patent/UA114607C2/uk unknown
- 2012-08-31 SI SI201231371T patent/SI2751094T1/sl unknown
- 2012-08-31 DK DK12756693.3T patent/DK2751094T3/en active
- 2012-08-31 PH PH1/2014/500382A patent/PH12014500382A1/en unknown
- 2012-08-31 EP EP12756693.3A patent/EP2751094B1/en active Active
- 2012-08-31 CA CA2847066A patent/CA2847066C/en not_active Expired - Fee Related
- 2012-08-31 SG SG2014011886A patent/SG2014011886A/en unknown
- 2012-08-31 RS RS20181064A patent/RS57644B1/sr unknown
- 2012-08-31 BR BR112014004251A patent/BR112014004251A2/pt not_active Application Discontinuation
- 2012-08-31 HU HUE12756693A patent/HUE041578T2/hu unknown
- 2012-08-31 KR KR1020197017797A patent/KR20190075172A/ko not_active Ceased
- 2012-08-31 AU AU2012300841A patent/AU2012300841C1/en not_active Ceased
- 2012-08-31 LT LTEP12756693.3T patent/LT2751094T/lt unknown
- 2012-08-31 MX MX2014002454A patent/MX349243B/es active IP Right Grant
- 2012-08-31 US US14/241,913 patent/US9227953B2/en not_active Expired - Fee Related
- 2012-08-31 SM SM20180455T patent/SMT201800455T1/it unknown
- 2012-08-31 KR KR1020147005011A patent/KR20140056297A/ko not_active Ceased
- 2012-08-31 HR HRP20181375TT patent/HRP20181375T1/hr unknown
- 2012-08-31 PL PL12756693T patent/PL2751094T3/pl unknown
-
2014
- 2014-02-13 IL IL230977A patent/IL230977A/en active IP Right Grant
- 2014-02-17 ZA ZA2014/01176A patent/ZA201401176B/en unknown
- 2014-02-27 CR CR20140098A patent/CR20140098A/es unknown
- 2014-02-27 CL CL2014000489A patent/CL2014000489A1/es unknown
- 2014-02-28 DO DO2014000042A patent/DOP2014000042A/es unknown
- 2014-02-28 CO CO14043369A patent/CO6890102A2/es not_active Application Discontinuation
- 2014-02-28 MA MA36784A patent/MA35362B1/fr unknown
-
2015
- 2015-11-25 US US14/951,997 patent/US9682074B2/en not_active Expired - Fee Related
-
2016
- 2016-01-28 AU AU2016200492A patent/AU2016200492B2/en not_active Ceased
- 2016-09-01 US US15/254,160 patent/US9694004B2/en not_active Expired - Fee Related
-
2018
- 2018-09-04 CY CY181100922T patent/CY1120784T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
| CL2013001947A1 (es) | Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona. | |
| CL2015000331A1 (es) | Compuestos derivados de piridazina 1,4-disustitutidos; composicion y combinacion farmaceutica que los comprende y uso en el tratamiento de la atrofia muscular espinal. | |
| CL2013001654A1 (es) | Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
| GT201200313A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| CL2014001047A1 (es) | Compuestos heterociclicos derivados de pirazina; composicion y combinacion farmaceutica que los contienen y el uso en enfermedades respiratorias y alergicas. | |
| CL2014000246A1 (es) | Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros | |
| BR112013020809A2 (pt) | composição para uso no tratamento ou prevenção de disturbio ou doença relacionada a uma mucosa | |
| HUE056006T2 (hu) | Kombináció Parkinson-kór kezelésére | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
| BR112014030406A2 (pt) | combinação de canabidiol fitocanabinoide com hipotermia terapêutica | |
| CL2014002386A1 (es) | Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras. | |
| CL2014000447A1 (es) | Compuestos derivados de piridina y pirimidina sustituidos, mediadores de quinurenina-3-monooxigenasa; composiciones farmaceuticas que los comprenden; y uso en el tratamiento de una patologia neurodegenerativa, tal como la enfermedad de huntington. | |
| CL2014001060A1 (es) | Compuestos derivados de aril-quinolina; proceso de obtencion; composicion farmaceutica que los comprende y uso en el tratamiento o profilaxis de la diabetes tipo 2, la aterosclerosis, cancer, entre otras enfermedades. | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| HUE063369T2 (hu) | Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben | |
| CL2014003429A1 (es) | Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia. | |
| IL240949B (en) | Aqueous pharmaceutical formulation for use in the treatment of type 1 or type 2 juvenile diabetes | |
| CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
| CL2014003325A1 (es) | Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer | |
| BR112015003957A2 (pt) | alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria |